Business ❯ Pharmaceutical Industry

Market Competition

Drug Pricing Pricing Strategies Novo Nordisk Eli Lilly Drug Sales Drug Development Drug Launches Drug Approval Weight Loss Drugs Product Development Stock Performance Stock Market Drug Approval Process Product Launches Weight Loss Market Obesity Treatments Investment Strategies Generic Drugs CGRP Inhibitors Monopolies Investor Expectations Weight-loss Drugs GLP-1 Drugs Pain Relief Products Acquisitions Generic Drug Market Drug Manufacturing Vaccine Market Pricing Agreements Obesity Drugs Eli Lilly vs Novo Nordisk Research and Development Telehealth Services Pricing Branding Drug Alternatives Drug Efficacy Weight Loss Drug Market RSV Vaccines GLP-1 Market Anti-Obesity Drugs Product Launch Product Hop Regulatory Measures Drug Launch Investor Relations

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

Novo says the lower list price is intended to broaden access to obesity care nationwide.

Roche’s Oral BTK Drug Succeeds in Phase 3 MS Trials, Matching Ocrevus in Progressive Disease

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Oral Semaglutide 25 mg Shows Larger Metabolic Gains With At Least 15% Weight Loss in OASIS-4

FDA Names First 9 Drugs for ‘National Priority’ Fast-Track Reviews, Targeting 1–2-Month Decisions